Arkolith/Insider Trading/QNCX/Form 4

Roberts Brigette

Chief Corp. Affairs Officer, DirectorQuince Therapeutics, Inc. (QNCX) · full profile →Form 4 · filed Jun 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
0 non-derivative · 9 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 18, 2026Grant(A)35K——35K
May 18, 2026Grant(A)229K——229K
May 18, 2026Grant(A)125K——125K
May 18, 2026Grant(A)69K——69K
May 18, 2026Grant(A)362K——362K
May 18, 2026Grant(A)134K——134K
May 18, 2026Grant(A)2.1M——2.1M
May 18, 2026Grant(A)6.8M——6.8M
May 18, 2026Grant(A)6.8M——6.8M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001346566-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Quince Therapeutics, Inc.

Build

Ask your agent about QNCX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001346566-26-000004"
Ask your agent
Use Arkolith to summarize insider buying and selling at Quince Therapeutics, Inc.
over the last 90 days and cite the filings.